Published in J Affect Disord on August 18, 1995
To assess, to control, to exclude: effects of biobehavioral factors on circulating inflammatory markers. Brain Behav Immun (2009) 3.00
The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology (2011) 2.15
Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study. Psychol Med (2008) 2.06
Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol Psychiatry (2008) 1.80
Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One (2010) 1.62
Individual differences in the peripheral immune system promote resilience versus susceptibility to social stress. Proc Natl Acad Sci U S A (2014) 1.50
Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology (Berl) (2003) 1.46
Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci (1997) 1.41
Epigenetic and inflammatory marker profiles associated with depression in a community-based epidemiologic sample. Psychol Med (2010) 1.38
Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC Med (2012) 1.37
A detailed examination of cytokine abnormalities in Major Depressive Disorder. Eur Neuropsychopharmacol (2007) 1.36
Antagonistic characteristics are positively associated with inflammatory markers independently of trait negative emotionality. Brain Behav Immun (2008) 1.35
Pro- and anti-inflammatory cytokine balance in major depression: effect of sertraline therapy. Clin Dev Immunol (2007) 1.34
Anxiety and depression in patients with rheumatoid arthritis. Clin Rheumatol (2006) 1.31
Cytokine-induced depression during IFN-alpha treatment: the role of IL-6 and sleep quality. Brain Behav Immun (2009) 1.31
A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. Int J Neuropsychopharmacol (2009) 1.28
A critical review of human endotoxin administration as an experimental paradigm of depression. Neurosci Biobehav Rev (2009) 1.24
Neuronal damage and protection in the pathophysiology and treatment of psychiatric illness: stress and depression. Dialogues Clin Neurosci (2009) 1.23
I'm so tired: biological and genetic mechanisms of cancer-related fatigue. Qual Life Res (2010) 1.16
Sustained low-grade pro-inflammatory state in unmedicated, remitted women with major depressive disorder as evidenced by elevated serum levels of the acute phase proteins C-reactive protein and serum amyloid A. Biol Psychiatry (2006) 1.13
Glucocorticoid dysregulations and their clinical correlates. From receptors to therapeutics. Ann N Y Acad Sci (2009) 1.12
Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder. Brain Behav Immun (2015) 1.10
Heart rate variability and markers of inflammation and coagulation in depressed patients with coronary heart disease. J Psychosom Res (2007) 1.09
Depression and heart rate variability in patients with coronary heart disease. Cleve Clin J Med (2009) 1.07
The concept of depression as a dysfunction of the immune system. Curr Immunol Rev (2010) 1.06
Neuroimmune mechanisms of depression. Nat Neurosci (2015) 1.05
Inflammation and reactivation of latent herpesviruses in older adults. Brain Behav Immun (2011) 1.02
A psychoneuroimmunological perspective to Emil Kraepelins dichotomy: schizophrenia and major depression as inflammatory CNS disorders. Eur Arch Psychiatry Clin Neurosci (2008) 1.01
A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry (2016) 0.99
Psychobiology of depression/distress in congestive heart failure. Heart Fail Rev (2008) 0.92
Major depression during interferon-alpha treatment: vulnerability and prevention. Dialogues Clin Neurosci (2009) 0.92
Point mutation in the mouse P2X7 receptor affects intercellular calcium waves in astrocytes. ASN Neuro (2009) 0.91
The impact of neuroimmune dysregulation on neuroprotection and neurotoxicity in psychiatric disorders--relation to drug treatment. Dialogues Clin Neurosci (2009) 0.90
Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target? Expert Rev Neurother (2012) 0.89
Abnormal gene expression of proinflammatory cytokines and their receptors in the lymphocytes of patients with bipolar disorder. Bipolar Disord (2015) 0.87
A biological pathway linking inflammation and depression: activation of indoleamine 2,3-dioxygenase. Neuropsychiatr Dis Treat (2011) 0.85
Proinflammatory cytokines and their membrane-bound receptors are altered in the lymphocytes of schizophrenia patients. Schizophr Res (2015) 0.84
Relations of depressive symptoms and antidepressant use to body mass index and selected biomarkers for diabetes and cardiovascular disease. Am J Public Health (2013) 0.84
Mitochondrial respiration in peripheral blood mononuclear cells correlates with depressive subsymptoms and severity of major depression. Transl Psychiatry (2014) 0.83
Integrating Interleukin-6 into depression diagnosis and treatment. Neurobiol Stress (2016) 0.83
Depression, cytokines, and pancreatic cancer. Psychooncology (2013) 0.82
Depression and coronary heart disease. ISRN Cardiol (2012) 0.82
Antidepressant therapy in epilepsy: can treating the comorbidities affect the underlying disorder? Br J Pharmacol (2013) 0.81
Somatic drugs for psychiatric diseases: aspirin or simvastatin for depression? Curr Neuropharmacol (2012) 0.81
Association of elevated cytokines with childhood adversity in a sample of healthy adults. J Psychiatr Res (2013) 0.81
Serotonin-immune interactions in major depression: lower serum tryptophan as a marker of an immune-inflammatory response. Eur Arch Psychiatry Clin Neurosci (1997) 0.81
The pro-inflammatory profile of depressed patients is (partly) related to obesity. J Psychiatr Res (2015) 0.80
Depression and the Link with Cardiovascular Disease. Front Psychiatry (2016) 0.80
Immune and Neuroendocrine Mechanisms of Stress Vulnerability and Resilience. Neuropsychopharmacology (2016) 0.80
Gender-specific cytokine pathways, targets, and biomarkers for the switch from health to adenoma and colorectal cancer. Clin Dev Immunol (2011) 0.80
Phagocytosis and killing of Staphylococcus aureus: effects of stress and depression in children. Clin Diagn Lab Immunol (1997) 0.79
Erythropoietin Pathway: A Potential Target for the Treatment of Depression. Int J Mol Sci (2016) 0.79
Pathogen-Host Defense in the Evolution of Depression: Insights into Epidemiology, Genetics, Bioregional Differences and Female Preponderance. Neuropsychopharmacology (2016) 0.78
Soluble urokinase plasminogen activator receptor as a marker for use of antidepressants. PLoS One (2014) 0.78
Effort-related motivational effects of the pro-inflammatory cytokine interleukin-6: pharmacological and neurochemical characterization. Psychopharmacology (Berl) (2016) 0.78
Inflammation and neuronal plasticity: a link between childhood trauma and depression pathogenesis. Front Cell Neurosci (2015) 0.78
Molecular Neurobiology and Promising New Treatment in Depression. Int J Mol Sci (2016) 0.78
Cellular and Molecular Inflammatory Profile of the Choroid Plexus in Depression and Suicide. Front Psychiatry (2015) 0.77
Shen-Qi-Jie-Yu-Fang has antidepressant effects in a rodent model of postpartum depression by regulating the immune organs and subsets of T lymphocytes. Neuropsychiatr Dis Treat (2015) 0.76
Stress-Related Immune Markers in Depression: Implications for Treatment. Int J Neuropsychopharmacol (2016) 0.76
Cytokines, neurophysiology, neuropsychology, and psychiatric symptoms. Dialogues Clin Neurosci (2003) 0.76
The role of cytokines and hot flashes in perimenopausal depression. Ann Gen Psychiatry (2012) 0.76
The links between chronic obstructive pulmonary disease and comorbid depressive symptoms: role of IL-2 and IFN-γ. Clin Exp Med (2015) 0.75
Interaction between interleukin-1β and type-1 cannabinoid receptor is involved in anxiety-like behavior in experimental autoimmune encephalomyelitis. J Neuroinflammation (2016) 0.75
Systems Genomics Support for Immune and Inflammation Hypothesis of Depression. Curr Neuropharmacol (2016) 0.75
The effect of sunlight exposure on interleukin-6 levels in depressive and non-depressive subjects. BMC Psychiatry (2013) 0.75
Editorial (Thematic Selection: Inflammatory and Immune Responses in Depression). Curr Neuropharmacol (2016) 0.75
The Role of Family Routines in the Intergenerational Transmission of Depressive Symptoms between Parents and their Adolescent Children. J Abnorm Child Psychol (2016) 0.75
Region-specific alterations of A-to-I RNA editing of serotonin 2c receptor in the cortex of suicides with major depression. Transl Psychiatry (2016) 0.75
Chelidonic acid evokes antidepressant-like effect through the up-regulation of BDNF in forced swimming test. Exp Biol Med (Maywood) (2016) 0.75
Peripheral zinc and neopterin concentrations are associated with mood severity in bipolar disorder in a gender-specific manner. Psychiatry Res (2017) 0.75
Retracted Relationship between inflammatory cytokines and risk of depression, and effect of depression on the prognosis of high grade glioma patients. J Neurooncol (2015) 0.75
Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry (1999) 5.63
Campylobacter enteritis in Central Africa. Lancet (1978) 3.20
The effects of psychological stress on humans: increased production of pro-inflammatory cytokines and a Th1-like response in stress-induced anxiety. Cytokine (1998) 2.70
Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine (1997) 2.43
Antibiotic susceptibility of Neisseria gonorrhoeae strains from Europe and Africa. Antimicrob Agents Chemother (1979) 2.31
Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther (1994) 2.27
Outcome in manic disorders. A naturalistic follow-up study. Arch Gen Psychiatry (1990) 2.15
A novel augmentation strategy for treating resistant major depression. Am J Psychiatry (2001) 2.05
Neuroleptic-induced prolactin level elevation and breast cancer: an emerging clinical issue. Arch Gen Psychiatry (1978) 2.02
Depth asymmetries of the pore-lining segments of the Na+ channel revealed by cysteine mutagenesis. Neuron (1996) 1.98
Inflammation markers in relation to cognition in a healthy aging population. J Neuroimmunol (2003) 1.89
Clozapine: is another view valid? Am J Psychiatry (1995) 1.84
Glial fibrillary acidic protein immunoreactivity in the prefrontal cortex distinguishes younger from older adults in major depressive disorder. Biol Psychiatry (2000) 1.68
The dopamine hypothesis of schizophrenia: a review. Schizophr Bull (1976) 1.65
Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy. Am J Psychiatry (1994) 1.64
Elevated serum interleukin-6 (IL-6) and IL-6 receptor concentrations in posttraumatic stress disorder following accidental man-made traumatic events. Biol Psychiatry (1999) 1.62
RNA editing of the human serotonin 5-HT2C receptor. alterations in suicide and implications for serotonergic pharmacotherapy. Neuropsychopharmacology (2001) 1.62
Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. J Neurosci (1997) 1.60
Time trends in the occurrence and outcome of acute myocardial infarction and coronary heart disease death between 1986 and 1996 (a New Jersey statewide study). Am J Cardiol (2001) 1.56
Meta-analyses of studies of ventricular enlargement and cortical sulcal prominence in mood disorders. Comparisons with controls or patients with schizophrenia. Arch Gen Psychiatry (1995) 1.55
Duration of a clozapine trial in neuroleptic-resistant schizophrenia. Arch Gen Psychiatry (1989) 1.48
Prefrontal sulcal prominence is inversely related to response to clozapine in schizophrenia. Biol Psychiatry (1991) 1.48
5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem (2001) 1.43
The role of cognition in vocational functioning in schizophrenia. Schizophr Res (2000) 1.43
Pathogenesis of abnormal vaginal bacterial flora. Am J Obstet Gynecol (2000) 1.42
The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology (Berl) (2004) 1.42
A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol (2002) 1.41
Fatty acid composition in major depression: decreased omega 3 fractions in cholesteryl esters and increased C20: 4 omega 6/C20:5 omega 3 ratio in cholesteryl esters and phospholipids. J Affect Disord (1996) 1.40
Anti-Inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio. J Clin Psychopharmacol (2001) 1.39
Effect of clozapine on psychogenic polydipsia in chronic schizophrenia. J Clin Psychopharmacol (1991) 1.39
Molecular motions within the pore of voltage-dependent sodium channels. Biophys J (1997) 1.39
Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology (2001) 1.37
Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry (1993) 1.33
Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. Eur J Biochem (2000) 1.32
The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull (1989) 1.31
Indicators of immune activation in major depression. Psychiatry Res (1996) 1.30
Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion. Neuropsychopharmacology (1999) 1.30
Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats. J Pharmacol Exp Ther (1997) 1.29
Interleukin-1 beta: a putative mediator of HPA axis hyperactivity in major depression? Am J Psychiatry (1993) 1.29
Decreased expression of the memory marker CD26 on both CD4+ and CD8+ T lymphocytes of HIV-infected subjects. J Acquir Immune Defic Syndr (1993) 1.29
The relationship between smooth pursuit performance, motion perception and sustained visual attention in patients with schizophrenia and normal controls. Psychol Med (1997) 1.28
Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor. J Neurochem (1996) 1.26
The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch Gen Psychiatry (1976) 1.25
Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res (1995) 1.25
Acupressure for prevention of pre-operative anxiety: a prospective, randomised, placebo controlled study. Anaesthesia (2005) 1.25
Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia. Mol Psychiatry (2001) 1.25
Eye-tracking dysfunctions in schizophrenic patients and their relatives. Arch Gen Psychiatry (1974) 1.24
Increased 24-hour urinary cortisol excretion in patients with post-traumatic stress disorder and patients with major depression, but not in patients with fibromyalgia. Acta Psychiatr Scand (1998) 1.24
Lowered omega3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res (1999) 1.24
Increased serum albumin, gamma globulin, immunoglobulin IgG, and IgG2 and IgG4 in autism. Psychol Med (2002) 1.22
Semen parameters in a fertile versus subfertile population: a need for change in the interpretation of semen testing. Hum Reprod (1997) 1.22
Intrauterine insemination after ovarian stimulation with clomiphene citrate: predictive potential of inseminating motile count and sperm morphology. Hum Reprod (1997) 1.21
HBV-specific lymphoproliferative and cytokine responses in patients with chronic hepatitis B. J Hepatol (1998) 1.21
Effect of varying pacing waveform shapes on propagation and hemodynamics in the rabbit heart. Am J Cardiol (1997) 1.20
The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr Res (1998) 1.19
Alterations in plasma prolyl endopeptidase activity in depression, mania, and schizophrenia: effects of antidepressants, mood stabilizers, and antipsychotic drugs. Psychiatry Res (1995) 1.18
Mechanisms of sodium/calcium selectivity in sodium channels probed by cysteine mutagenesis and sulfhydryl modification. Biophys J (1997) 1.17
The genome-wide supported microRNA-137 variant predicts phenotypic heterogeneity within schizophrenia. Mol Psychiatry (2013) 1.16
In humans, serum polyunsaturated fatty acid levels predict the response of proinflammatory cytokines to psychologic stress. Biol Psychiatry (2000) 1.16
Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. Eur Neuropsychopharmacol (2001) 1.16
Seasonal variation in peripheral blood leukocyte subsets and in serum interleukin-6, and soluble interleukin-2 and -6 receptor concentrations in normal volunteers. Experientia (1994) 1.16
Elevation of serum prolactin and corticosterone concentrations in the rat after the administration of 3,4-methylenedioxymethamphetamine. J Pharmacol Exp Ther (1988) 1.15
Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res (2001) 1.14
The inflammatory response following delivery is amplified in women who previously suffered from major depression, suggesting that major depression is accompanied by a sensitization of the inflammatory response system. J Affect Disord (2001) 1.14
Lower serum high-density lipoprotein cholesterol (HDL-C) in major depression and in depressed men with serious suicidal attempts: relationship with immune-inflammatory markers. Acta Psychiatr Scand (1997) 1.14
Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res (1997) 1.13
Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors. J Pharmacol Exp Ther (1992) 1.13
Thermoregulatory responses to serotonin (5-HT) receptor stimulation in the rat. Evidence for opposing roles of 5-HT2 and 5-HT1A receptors. Neuropharmacology (1986) 1.12
Interleukin (IL)-6, IL-8 and IL-10 in serum and CSF of Trypanosoma brucei gambiense sleeping sickness patients before and after treatment. Trans R Soc Trop Med Hyg (2002) 1.10
Components of biological variation, including seasonality, in blood concentrations of TSH, TT3, FT4, PRL, cortisol and testosterone in healthy volunteers. Clin Endocrinol (Oxf) (1997) 1.10
The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats. J Pharmacol Exp Ther (2011) 1.10
Effect of clozapine on human serum prolactin levels. Am J Psychiatry (1979) 1.09
Seasonality in violent suicide but not in nonviolent suicide or homicide. Am J Psychiatry (1993) 1.09
Lower serum prolyl endopeptidase enzyme activity in major depression: further evidence that peptidases play a role in the pathophysiology of depression. Biol Psychiatry (1994) 1.08
Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: further evidence for an immune response. Psychiatry Res (1994) 1.08
Neonatal screening for alpha-1-antitrypsin deficiency. Eur J Pediatr (1988) 1.07
Treatment of schizophrenia and spectrum disorders: pharmacotherapy, psychosocial treatments, and neurotransmitter interactions. Biol Psychiatry (1999) 1.07
Combination of serum markers related to several mechanisms in Alzheimer's disease. Neurobiol Aging (2003) 1.07
The effect of buspirone on prolactin and growth hormone secretion in man. Arch Gen Psychiatry (1983) 1.07
Multicenter study on reproducibility of sperm morphology assessments. Arch Androl (1998) 1.07
Factors affecting serum creatine phosphokinase levels in the general population: the role of race, activity and age. Clin Chim Acta (1971) 1.06
Immune activation in the early puerperium is related to postpartum anxiety and depressive symptoms. Psychoneuroendocrinology (2000) 1.06
Decreased CD40 ligand induction in CD4 T cells and dysregulated IL-12 production during HIV infection. Clin Exp Immunol (1999) 1.05
Plasma concentrations of excitatory amino acids, serine, glycine, taurine and histidine in major depression. Eur Neuropsychopharmacol (1995) 1.05
Radio-responsive recA promoter significantly increases TNFalpha production in recombinant clostridia after 2 Gy irradiation. Gene Ther (2001) 1.05
Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry (2001) 1.04
Elevated levels of tyrosine hydroxylase in the locus coeruleus in major depression. Biol Psychiatry (1999) 1.04
Improvement of Clostridium tumour targeting vectors evaluated in rat rhabdomyosarcomas. FEMS Immunol Med Microbiol (2001) 1.04
Overexpression of cysteine-string proteins in Drosophila reveals interactions with syntaxin. J Neurosci (1999) 1.04
Altered receptor expression and decreased sensitivity of T-cells to the stimulatory cytokines IL-2, IL-7 and IL-12 in HIV infection. Immunol Lett (1998) 1.04